Specialized ETP solutions engineered for API manufacturing units, formulation facilities, and R&D laboratories. ZEXCORP delivers CPCB-compliant treatment systems including Zero Liquid Discharge (ZLD) for India's pharmaceutical sector.
Request a Free Site Assessment →The pharmaceutical industry generates some of the most complex and hazardous industrial effluents. Standard treatment methods fail to address the unique challenges of drug manufacturing wastewater.
API manufacturing wastewater typically carries COD levels of 10,000–80,000 mg/L — up to 200 times higher than domestic sewage. Solvents, intermediates, and unreacted raw materials create a highly concentrated effluent that overwhelms conventional biological systems.
Active pharmaceutical ingredients, catalysts, heavy metals, and chlorinated solvents are inherently toxic to microorganisms. Many compounds resist biological degradation entirely, requiring advanced oxidation or chemical treatment before any biological stage can function.
Pharmaceutical batch processes generate effluent with pH ranging from 2 to 12, with characteristics changing dramatically between production batches. This variability demands robust equalization and treatment systems designed for worst-case scenarios, not averages.
A single pharmaceutical facility may generate 5–10 distinct waste streams: mother liquor, spent solvents, wash water, utility blowdown, and floor washings — each requiring different pre-treatment before combining for final treatment.
Antibiotic manufacturing effluent poses a unique environmental risk — promoting antimicrobial resistance (AMR) in receiving water bodies. CPCB has introduced specific monitoring requirements for antibiotic residues in pharma ETP discharge.
CPCB mandates Zero Liquid Discharge (ZLD) for bulk drug manufacturers generating over 25 KLD effluent. State Pollution Control Boards enforce increasingly strict discharge norms, with heavy penalties for non-compliance and potential facility closure.
ZEXCORP designs multi-stage treatment systems that combine physical, chemical, and biological processes to handle the full spectrum of pharmaceutical effluent challenges.
Fenton's reagent, ozonation, and UV/H₂O₂ systems to break down recalcitrant organics and improve biodegradability. Achieves 40–60% COD reduction of bio-refractory compounds before biological treatment.
Combines high-rate biological treatment with ultrafiltration membranes for superior effluent quality. Compact footprint ideal for pharmaceutical facilities with space constraints. Achieves BOD <5 mg/L consistently.
Granular and powdered activated carbon systems for polishing treatment — removing residual organics, color, and trace pharmaceutical compounds. Essential for meeting stringent COD and bioassay standards.
Energy-efficient evaporation systems for high-TDS reject concentration in ZLD applications. Reduces reject volume by 85–90%, with recovered condensate suitable for reuse in utilities.
Final stage of ZLD systems — converts concentrated brine into dry salt cake for disposal. Achieves true zero liquid discharge with salt recovery rates exceeding 95%.
Moving Bed Biofilm Reactor with specialized biocarriers for high-strength pharmaceutical wastewater. Handles organic loading rates of 5–15 kg COD/m³/day with excellent shock load resilience.
Distillation-based recovery of valuable solvents from mother liquor and wash streams. Reduces effluent organic load by 50–70% while recovering reusable solvents worth ₹30–100/L.
Ultrafiltration and reverse osmosis for tertiary polishing and water recovery. Achieves 70–85% water reuse from treated effluent, significantly reducing freshwater consumption and ZLD system load.
Representative results from ZEXCORP pharmaceutical ETP installations showing consistent compliance with CPCB discharge standards.
| Parameter | Raw Effluent (Inlet) | Treated Effluent (Outlet) | CPCB Standard | Removal % |
|---|---|---|---|---|
| pH | 2.0 – 12.0 | 6.5 – 7.5 | 6.0 – 8.5 | — |
| COD (mg/L) | 25,000 – 60,000 | < 200 | ≤ 250 | > 99.5% |
| BOD (mg/L) | 8,000 – 20,000 | < 20 | ≤ 30 | > 99.8% |
| TSS (mg/L) | 500 – 2,000 | < 50 | ≤ 100 | > 97% |
| TDS (mg/L) | 5,000 – 25,000 | < 2,100 | ≤ 2,100 | > 90% |
| Color (Pt-Co) | 500 – 3,000 | < 50 | Colorless | > 98% |
| Bioassay | Toxic | 90%+ fish survival | 90% survival (96h) | Pass |
From initial feasibility study to commissioning and AMC — ZEXCORP delivers end-to-end ETP solutions for the pharmaceutical industry. Contact us for a free site assessment and techno-commercial proposal.